{
  "author": {
    "name": "Molly Castle Work",
    "webUrl": "/author/profile/molly-castle-work/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 1,
    "social": [],
    "articles": [
      {
        "uri": "/2024/01/23/what-the-health-care-sector-was-selling-at-the-j-p-morgan-confab/",
        "title": "Top trends from JPM Healthcare Conference: What the industry can expect in 2024",
        "byline": "Molly Castle Work and Arthur Allen",
        "kicker": "Market Insights",
        "prettyDate": "January 23, 2024",
        "timeToRead": "7 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2024/01/Healthcare-Article-202311150851.jpg",
          "width": "620",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/molly-castle-work/",
            "name": "Molly Castle Work"
          },
          {
            "webUrl": "/author/profile/arthur-allen/",
            "name": "Arthur Allen"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "At the 42nd annual event for investors, pharma executives and biotech innovators, the spotlight was on AI, the new GLP-1 class of weight loss drugs, non-profit hospitals and treatment for autoimmune disease.",
        "body": null
      }
    ]
  }
}